New advances in allergy immunotherapy

Abstract

Developments in the field of specific immunotherapy for allergic disease are accelerating rapidly because of advances in technology, but also because of the recognition that this disease-modifying therapy is a well tolerated, efficacious, and cost-effective option for individuals, which can improved their quality of life in a long-term fashion. VIDEO ABSTRACT.

New and old adjuvants in allergen‐specific immunotherapy: With a focus on nanoparticles

“…Adjuvants belong to an extremely diverse collection of chemically complex materials (Perrie, Mohammed, Kirby, McNeil, & Bramwell, 2008). These materials can be categorized into different substances with respect to their means of adjuvanticity action according to their mechanisms (Cox, Verdonck, Vanrompay, & Goddeeris, 2006;Moingeon, 2012 (Reisacher & Schwanke, 2016). However, some compounds can act by more than one mechanism concurrently (Aguilar & Rodriguez, 2007;Perrie et al, 2008).…”

“…In addition, adjuvants in Group (III) act as immunostimulators (e.g., muramyl dipeptide (MOP), monophosphoryl lipid A [MPL], Freund's complete adjuvant, lipopolysaccharide, cytokines, and lipid A; de Souza Apostólico, Lunardelli, Coirada, Boscardin, & Rosa, 2016). Immunostimulatory (Immunopotentiator) adjuvants, which increase the immunogenicity of specific allergens, while not being pharmacologically active themselves, have been used for many years in SIT vaccines (Reisacher & Schwanke, 2016). However, some compounds can act by more than one mechanism concurrently (Aguilar & Rodriguez, 2007; Perrie et al, 2008).…”